Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_assertion type Assertion NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_head.
- NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_assertion description "[The results showed that the gene therapy resulted in (1) suppression of T and B cell activation and T cell proliferation; (2) a reduction in serum levels of proinflammatory cytokines; (3) improvement of proteinuria and renal dysfunction; (4) prevention of glomerular crescent formation, renal interstitial inflammation, and glomerulosclerosis; (5) a reduction in serum levels of autoantibodies and glomerular immune deposits; (6) inhibition of apoptosis in the spleen and kidney; (7) prevention of T cell and macrophage infiltration of the kidney; and (8) suppression of fibrosis-related gene expression in the kidney compared with empty vector-treated (disease control) ACGN mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_provenance.
- NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_assertion evidence source_evidence_literature NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_provenance.
- NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_assertion SIO_000772 17687076 NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_provenance.
- NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_assertion wasDerivedFrom befree-20150227 NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_provenance.
- NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_assertion wasGeneratedBy ECO_0000203 NP894330.RAPpMdLLAeOF3y-z_DXq6BtV2uJbbBBZiN5jqTNfc-RBU130_provenance.